Cargando…
RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
OBJECTIVE: The RAD51 assay is a recently developed functional assay for homologous recombination deficiency (HRD) that reflects real-time HRD status. We aimed to identify the applicability and predictive value of RAD51 immunohistochemical expression in pre- and post-neoadjuvant chemotherapy (NAC) sa...
Autores principales: | Kim, Kyeongmin, Kim, Se Hoon, Lee, Jung-Yun, Kim, Yoo-Na, Lee, Seung-Tae, Park, Eunhyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323304/ https://www.ncbi.nlm.nih.gov/pubmed/36807748 http://dx.doi.org/10.3802/jgo.2023.34.e45 |
Ejemplares similares
-
RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
por: Kramer, Claire JH, et al.
Publicado: (2023) -
Chromatin organization revealed by nanostructure of irradiation induced γH2AX, 53BP1 and Rad51 foci
por: Reindl, Judith, et al.
Publicado: (2017) -
Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021) -
RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
por: Compadre, Amanda J., et al.
Publicado: (2023) -
Spotlight on Geminin
por: DePamphilis, Melvin L
Publicado: (2011)